Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (Q60620763)
Jump to navigation
Jump to search
scientific article published on 16 February 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer |
scientific article published on 16 February 2010 |
Statements
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer (English)
Jean-Charles Soria
Egbert Smit
David Khayat
Benjamin Besse
Xinqun Yang
Cheng-Pang Hsu
David Reese
Jeffrey Wiezorek
16 February 2010